MannKind Corp (NASDAQ:MNKD)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.

Recs

0
Player Avatar JorgeAura (< 20) Submitted: 12/6/2012 7:33:16 PM : Underperform Start Price: $2.08 MNKD Score: -129.70

Extremly overvalued. Market Cap   $508.8M.

Featured Broker Partners


Advertisement